In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...

Discover the commercial and brand names of the generic drug Insulin Glargine. This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

QWINT-1 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients. The trial met its primary endpoint of non ...

(a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee (R) (insulin glargine-yfgn injection) as the first interchangeable biosimilar ...

Insulin Glargine injection: Biocon and Sanofi-Aventis reported shortages of their Insulin Glargine products due to increased demand. Alternative insulin options such as Basaglar and Rezvoglar ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...